| Report ID | Date of report | Patient age | Patient gender |
| 102084 | Apr, 18, 2006 | 55 | Male |
List of drugs the patient takes:
| Drug | Ingredient(s) |
Vinblastine Sulfate | vinblastine sulfate |
Abacavir | abacavir sulfate |
Lamivudine | lamivudine |
Nevirapine | nevirapine |
Zidovudine | zidovudine |
| Name |
Bone Marrow Failure |
C-reactive Protein Increased |
Castleman's Disease |
Constipation |
Disease Recurrence |
Drug Interaction |
Escherichia Sepsis |
Fatigue |
Febrile Bone Marrow Aplasia |
General Physical Health Deterioration |
Herpes Virus Infection |
Lymphadenopathy |
Lymphadenopathy Mediastinal |
Neuropathy Peripheral |
Neutropenia |
Pancytopenia |
Renal Failure |
Septic Shock |
Serum Ferritin Increased |
Splenomegaly |
Tachycardia |
Results from eHealthMe : 129 report(s)
Comparison with the patient:
| Name | Count (% of total reports) |
Bone Marrow Failure | 129 (100.00%) |
C-reactive Protein Increased | 129 (100.00%) |
Castleman's Disease | 129 (100.00%) |
Constipation | 129 (100.00%) |
Disease Recurrence | 129 (100.00%) |
Drug Interaction | 129 (100.00%) |
Escherichia Sepsis | 129 (100.00%) |
Fatigue | 129 (100.00%) |
Febrile Bone Marrow Aplasia | 129 (100.00%) |
General Physical Health Deterioration | 129 (100.00%) |
Herpes Virus Infection | 129 (100.00%) |
Lymphadenopathy | 129 (100.00%) |
Lymphadenopathy Mediastinal | 128 (99.22%) |
Neuropathy Peripheral | 129 (100.00%) |
Neutropenia | 129 (100.00%) |
Pancytopenia | 129 (100.00%) |
Renal Failure | 129 (100.00%) |
Septic Shock | 129 (100.00%) |
Serum Ferritin Increased | 129 (100.00%) |
Splenomegaly | 129 (100.00%) |
Tachycardia | 129 (100.00%) |
Top 3 (total: 0. Click here to see more) co-used drugs - potential interacting drugs:
Death reported: 0
| Name | Count (% of total reports) |
Neutropenia | 129 (100.00%) |
Neuropathy Peripheral | 129 (100.00%) |
Lymphadenopathy | 129 (100.00%) |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent drug risk analysis reports:
